Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)

被引：0
|
作者：
Warren, Richard B. [1 ]
de Bruin-Weller, Marjolein [2 ]
Tsianakas, Athanasios [3 ]
Khemis, Abdallah [4 ]
Szepietowski, Jacek C. [5 ]
Hong, H. Chih-Ho [6 ]
Armengol, Clara [7 ]
Falques, Meritxell [7 ]
Agell, Helena [7 ]
Massana, Eric [7 ]
Gil, Esther Garcia [7 ]
Weidinger, Stephan [8 ]
机构：
[1] Univ Manchester, Northern Care Alliance NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, England
[2] Univ Med Ctr Utrecht, Utrecht, Netherlands
[3] Fachklin Bad Bentheim, Bad Bentheim, Germany
[4] Polyclin St George Grp Kantys, Dermatol, Nice, France
[5] Med Univ, Wroclaw, Poland
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Almirall SA, Barcelona, Spain
[8] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
lebrikizumab; topical corticosteroids; investigator global assessment; eczema area and severity index; pruritis numeric rating scale;
D O I：
10.1093/bjd/ljae266.005
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
619
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Lebrikizumab in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3, Randomized, Placebo-Controlled Trial (ADhere)
    Simpson, Eric L.
    Gooderham, Melinda
    Wollenberg, Andreas
    Weidinger, Stephan
    Armstrong, April
    Soung, Jennifer
    Ferrucci, Silvia
    Lima, Renata Gontijo
    Xu, Wen
    Witte, Michael M.
    Blauvelt, Andrew
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 61
  • [2] Efficacy and safety of lebrikizumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis: a phase III randomized, placebo-controlled trial (ADhere)
    Simpson, Eric L.
    Gooderham, Melinda
    Wollenberg, Andreas
    Weidinger, Stephan
    Armstrong, April
    Soung, Jennifer
    Ferrucci, Silvia
    Lima, Renata Gontijo
    Xu, Wen
    Witte, Michael M.
    Blauvelt, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E108 - E108
  • [3] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [4] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    Dermatology and Therapy, 2023, 13 : 595 - 608
  • [5] LEBRIKIZUMAB IMPROVES PATIENT-REPORTED SYMPTOMS OF ANXIETY AND DEPRESSION IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM THREE RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 3 TRIALS
    Lio, Peter
    Armstrong, April
    Guenthner, Scott
    Gutermuth, Jan
    Zhong, Jinglin
    Pierce, Evangeline
    Dawson, Zach
    Witte, Michael
    Thyssen, Jacob P.
    Wollenberg, Andreas
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 31 - 31
  • [6] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials
    Silverberg, Jonathan
    Thaci, Diamant
    Seneschal, Julien
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric
    Chu, Chia-Yu
    Liu, Zhuqing
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Guttman-Yassky, Emma
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 62 - 62
  • [7] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
  • [8] Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial
    Tsianakas, A.
    Luger, T. A.
    Radin, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 406 - 414
  • [9] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: results from two phase III, randomized, double-blinded, placebo-controlled trials
    Silverberg, Jonathan I.
    Thaci, Diamant
    Seneschal, Julien
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric
    Chu, Chia-Yu
    Liu, Zhuqing T.
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Guttman-Yassky, Emma
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E97 - E98
  • [10] Lebrikizumab in combination with topical corticosteroids improves quality of life in patients with moderate-to-severe atopic dermatitis: results from a phase III randomized, double-blinded, placebo-controlled trial (ADhere)
    Forman, Seth
    Gutermuth, Jan
    de Bruin-Weller, Marjolein
    Moore, Angela
    Guenthner, Scott
    Wolf, Eric
    Pierce, Evangeline
    Witte, Michael M.
    Zhong, Jinglin
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E109
12345